Who
Eric J. Hyllengren
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Tenaya Therapeutics; Chief Financial Officer, Zura Bio; EVP, CFO and COO, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $88K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 16 May 2023
- Last trade
- 13 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Jul 2026filed 14 Jul 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,650,000 at $0.00 | filing |
| 13 Jul 2026filed 14 Jul 2026 | TNYA Tenaya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,650,000 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —340,900 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —340,900 at $0.00 | filing |
| 15 Jul 2025filed 17 Jul 2025 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —672,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,900 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —460 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —496 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —154 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —381 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —350 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —262 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —543 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —331 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,961 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $8,4771,211 at $7.00 | filing |
| 27 Jan 2025filed 29 Jan 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —34,050 at $0.00 | filing |
| 18 Nov 2024filed 20 Nov 2024 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $15K1,364 at $11.20 | filing |
| 16 Aug 2024filed 20 Aug 2024 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $6,9021,041 at $6.63 | filing |
| 16 Aug 2024filed 20 Aug 2024 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $19229 at $6.63 | filing |
News
No headline names them, or the companies they trade most, lately.